Publications
2022|2021|2020| 2019| 2018 | 2017 thru 2015 | 2014 thru 2010 | 2009 thru 2005 | 2004 thru 2001 |
2024
Valdes PA, Yu CJ, Aronson J, Ghosh D, Zhao Y, An B, Bernstock JD, Bhere D, Felicella MM, Viapiano MS, Shah K, Chiocca EA, Boyden ES. Improved immunostaining of nanostructures and cells in human brain specimens through expansion-mediated protein decrowding. Sci Transl Med. 2024 Jan 31;16(732):eabo0049. doi: 10.1126/scitranslmed.abo0049. Epub 2024 Jan 31. PMID: 38295184.
2023
Rossignoli F, Hoffman D, Atif E, Shah K. Developing and characterizing a two-layered safety switch for cell therapies. Cancer Biol Ther. 2023 Dec 31;24(1):2232146. doi: 10.1080/15384047.2023.2232146. PMID: 37439774.
Liu C, Shah K. Taming CAR T cell therapy toxicity. Nat Mater. 2023 Nov 30. doi: 10.1038/s41563-023-01742-7. Epub ahead of print. PMID: 38036624.
Melloni A, Liu L, Kashinath V, Abdi R, Shah K. Meningeal lymphatics and their role in CNS disorder treatment: moving past misconceptions. Front Neurosci. 2023 Jul 12;17:1184049. doi: 10.3389/fnins.2023.1184049. PMID: 37502683.
Moleirinho S, Kitamura Y, Borges PSGN, Auduong S, Kilic S, Deng D, Kanaya N, Kozono D, Zhou J, Gray JJ, Revai-Lechtich E, Zhu Y, Shah K. Fate and Efficacy of Engineered Allogeneic Stem Cells Targeting Cell Death and Proliferation Pathways in Primary and Brain Metastatic Lung Cancer. Stem Cells Transl Med. 2023 Jun 13:szad033. doi: 10.1093/stcltm/szad033. Epub ahead of print. PMID: 37311043.
Kanaya N, Kitamura Y, Lopez Vazquez M, Franco A, Chen KS, van Schaik TA, Aligholipour Farzani T, Borges P, Ichinose T, Seddiq W, Kuroda S, Boland G, Jahan N, Fisher D, Wakimoto H, Shah K. Gene-edited and -engineered stem cell platform drives immunotherapy for brain metastatic melanomas. Science Translational Medicine. 2023 May 31; DOI:10.1126/scitranslmed.ade8732 PMID: 37256936.
van Schaik TA, Moreno-Lama L, Aligholipour Farzani T, Wang M, Chen KS, Li W, Cai L, Zhang YS, Shah K. Engineered cell-based therapies in ex vivo ready-made CellDex capsules have therapeutic efficacy in solid tumors. Biomed Pharmacother. 2023 Apr 14;162:114665. doi: 10.1016/j.biopha.2023.114665. PMID: 37062216.
Kuruppu, D., Bhere, D., Farrar, C., Shah, K., Brownell, A., Mahmood, U., & Tanabe, K. (2023). Oncolytic HSV1 targets different growth phases of breast cancer leptomeningeal metastases. Cancer Gene Therapy. 2023 February 1; doi:10.1038/s41417-023-00588-0. PMID: 36721067.
Alkayyal AA, Ajina R, Cacciabue M, Alkayyal AA, Saeedi NH, Hussain Alshehry T, Kaboha F, Alotaibi MA, Zaidan N, Shah K, Alroqi F, Bakur Mahmoud A. SARS-CoV-2 RBD protein enhances the oncolytic activity of the vesicular stomatitis virus. Front Immunol. 2023 Jan 31;14:1082191. doi: 10.3389/fimmu.2023.1082191. PMID: 36798114.
Chen, K.S., Reinshagen, C., van Schaik, Thijs A., Rossignoli, F., Borges, P., Mendonca, N.C., Abdi, R., Simon, B., Reardon, David A., Wakimoto, H., and Shah, K. Bifunctional cancer cell–based vaccine concomitantly drives direct tumor killing and antitumor immunity. Science Translational Medicine. 2023 January 4; doi:10.1126/scitranslmed.abo4778. PMID: 36599004.
2022
Bhere D, Choi SH, van de Donk P, Hope D, Gortzak K, Kunnummal A, Khalsa J, Revai Lechtich E, Reinshagen C, Leon V, Nissar N, Bi WL, Feng C, Li H, Zhang YS, Liang SH, Vasdev N, Essayed W, Quevedo PV, Golby A, Banouni N, Palagina A, Abdi R, Fury B, Smirnakis S, Lowe A, Reeve B, Hiller A, Chiocca EA, Prestwich G, Wakimoto H, Bauer G, Shah K. Target receptor identification and subsequent treatment of resected brain tumors with encapsulated and engineered allogeneic stem cells. Nat Commun. 2022 May 19;13(1):2810. doi: 10.1038/s41467-022-30558-3. PMID: 35589724.
Liu L, Shah K. The Potential of the Gut Microbiome to Reshape the Cancer Therapy Paradigm: A Review. JAMA Oncol. 2022 Apr 28. doi: 10.1001/jamaoncol.2022.0494. Epub ahead of print. PMID: 35482355.
Arghiani, N., & Shah, K. (2021). Modulating microRNAs in cancer: Next-generation therapies. Cancer biology & medicine, 19(3), 289–304. Advance online publication. PMID: 8958885 https://doi.org/10.20892/j.issn.2095-3941.2021.0294
Liu, L., Huh, J. R., & Shah, K. (2022). Microbiota and the gut-brain-axis: Implications for new therapeutic design in the CNS. EBioMedicine, 77, 103908. PMID: 8897630 https://doi.org/10.1016/j.ebiom.2022.103908
Karakaş N, Üçüncüoğlu S, Uludağ D, Karaoğlan BS, Shah K, Öztürk G. Mesenchymal Stem Cell-Based COVID-19 Therapy: Bioengineering Perspectives. Cells. 2022 Jan 29;11(3):465. doi: 10.3390/cells11030465.PMID: 35159275
Hajji N, Garcia-Revilla J, Sarmiento Soto M, Perryman R, Symington JJ, Quarles CC, Healey DR, Guo Y, Orta-Vázquez ML, Mateos-Cordero S, Shah K, Bomalaski J, Anichini G, Tzakos AG, Crook T, O’Neill K, Scheck AC, Venero JL, Syed N. Arginine deprivation alters microglia polarity and synergises with radiation to eradicate non arginine auxotrophic glioblastoma tumors. J Clin Invest. 2022 Feb 3:e142137. doi: 10.1172/JCI142137. Online ahead of print.PMID: 35113813
Balatsoukas A, Rossignoli F, Shah K. NK cells in the brain: implications for brain tumor development and therapy. Trends Mol Med. 2022 Mar;28(3):194-209. doi: 10.1016/j.molmed.2021.12.008. Epub 2022 Jan 22.PMID: 35078713 Free PMC article. Review.
2021
Arghiani N, Shah K. Modulating microRNAs in cancer: Next-generation therapies. Cancer Biol Med. 2021 Dec 1:j.issn.2095-3941.2021.0294. doi: 10.20892/j.issn.2095-3941.2021.0294. Epub ahead of print. PMID: 34846108.
Kiyokawa J, Kawamura Y, Ghouse SM, Acar S, Barçın E, Martínez-Quintanilla J, Martuza RL, Alemany R, Rabkin SD, Shah K, Wakimoto H. Modification of Extracellular Matrix Enhances Oncolytic Adenovirus Immunotherapy in Glioblastoma. Clin Cancer Res. 2021 Feb 1;27(3):889-902. doi: 10.1158/1078-0432.CCR-20-2400. Epub 2020 Nov 30. PMID: 33257429; PMCID: PMC7854507.
Akter F, Simon B, de Boer NL, Redjal N, Wakimoto H, Shah K. Pre-clinical tumor models of primary brain tumors: Challenges and opportunities. Biochim Biophys Acta Rev Cancer. 2021 Jan;1875(1):188458. doi: 10.1016/j.bbcan.2020.188458. Epub 2020 Oct 23. PMID: 33148506; PMCID: PMC7856042.
Aldrak N, Alsaab S, Algethami A, Bhere D, Wakimoto H, Shah K, Alomary MN, Zaidan N. Oncolytic Herpes Simplex Virus-Based Therapies for Cancer. Cells. 2021 Jun 18;10(6):1541. doi: 10.3390/cells10061541. PMID: 34207386; PMCID: PMC8235327.
Ishii Y, Kolluri KK, Pennycuick A, Zhang X, Nigro E, Alrifai D, Borg E, Falzon M, Shah K, Kumar N, Janes SM. BAP1 and YY1 regulate expression of death receptors in malignant pleural mesothelioma. J Biol Chem. 2021 Sep 29;297(5):101223. doi: 10.1016/j.jbc.2021.101223. Epub ahead of print. PMID: 34597666.
Karakaş N, Stuckey D, Revai-Lechtich E, Shah K. IL13Rα2‑ and EGFR‑targeted pseudomonas exotoxin potentiates the TRAIL‑mediated death of GBM cells. Int J Mol Med. 2021 Jul;48(1):145. doi: 10.3892/ijmm.2021.4978. Epub 2021 Jun 3.PMID: 34080646
Tawfik EA, Aldrak NA, Albrahim SH, Alzahrani DA, Alfassam HA, Alkoblan SM, Almalik AM, Chen KS, Abou-Khalil R, Shah K, Zaidan NM. Immunotherapy in hematological malignancies: recent advances and open questions. Immunotherapy. 2021 Oct;13(14):1215-1229. doi: 10.2217/imt-2021-0065. Epub 2021 Sep 9. PMID: 34498496.
Van Schaik TA, Chen KS, Shah K. Therapy-Induced Tumor Cell Death: Friend or Foe of Immunotherapy? Frontiers Oncology 2021 doi.org/10.3389/fonc.2021.678562
Vaughan HJ, Zamboni CG, Radant NP, Bhardwaj P, Revai Lechtich E, Hassan LF, Shah K, Green JJ. Poly(beta-amino ester) nanoparticles enable tumor-specific TRAIL secretion and a bystander effect to treat liver cancer. Mol Ther Oncolytics. 2021 Apr 16;21:377-388. doi: 10.1016/j.omto.2021.04.004. PMID: 34189258; PMCID: PMC8208964.
Cingöz A, Ozyerli-Goknar E, Morova T, Seker-Polat F, Esai Selvan M, Gümüş ZH, Bhere D, Shah K, Solaroglu I, Bagci-Onder T. Generation of TRAIL-resistant cell line models reveals distinct adaptive mechanisms for acquired resistance and re-sensitization. Oncogene. 2021 May;40(18):3201-3216. doi: 10.1038/s41388-021-01697-6. Epub 2021 Mar 25. PMID: 33767436.
Kitamura Y, Kanaya N, Moleirinho S, Du W, Reinshagen C, Attia N, Bronisz A, Revai Lechtich E, Sasaki H, Mora JL, Brastianos PK, Falcone JL, Hofer AM, Franco A, Shah K. Anti-EGFR VHH-armed death receptor ligand-engineered allogeneic stem cells have therapeutic efficacy in diverse brain metastatic breast cancers. Sci Adv. 2021 Mar 3;7(10):eabe8671. doi: 10.1126/sciadv.abe8671. Print 2021 Mar. PMID: 33658202
Khalsa JK, Shah K. Immune Profiling of Syngeneic Murine and Patient GBMs for Effective Translation of Immunotherapies. Cells. 2021 Feb 25;10(3):491. doi: 10.3390/cells10030491. PMID: 33668856
López Vázquez M, Du W, Kanaya N, Kitamura Y, Shah K. Next-Generation Immunotherapies for Brain Metastatic Cancers. Trends Cancer. 2021 Mar 12:S2405-8033(21)00045-5. doi: 10.1016/j.trecan.2021.02.003. Epub ahead of print. PMID: 33722479.
Song N, Wakimoto H, Rossignoli F, Bhere D, Ciccocioppo R, Chen KS, Khalsa JK, Mastrolia I, Samarelli AV, Dominici M, Shah K. Mesenchymal stem cell immunomodulation: In pursuit of controlling COVID-19 related cytokine storm. Stem Cells. 2021 Feb 14. doi: 10.1002/stem.3354. Online ahead of print. PMID: 33586320
Jiang L, Jung S, Zhao J, Kasinath V, Ichimura T, Joseph J, Fiorina P, Liss AS, Shah K, Annabi N, Joshi N, Akama TO, Bromberg JS, Kobayashi M, Uchimura K, Abdi R. Simultaneous targeting of primary tumor, draining lymph node, and distant metastases through high endothelial venule-targeted delivery. Nano Today. 2021 Feb;36:101045. doi: 10.1016/j.nantod.2020.101045. PMID: 33391389
2020
Akter F, Simon B, de Boer NL, Redjal N, Wakimoto H, Shah K. Pre-clinical tumor models of primary brain tumors: Challenges and opportunities. Biochim Biophys Acta Rev Cancer. 2020 Oct 23;1875(1):188458. doi: 10.1016/j.bbcan.2020.188458. Online ahead of print. PMID: 33148506
Jiang L, Wang YJ, Zhao J, Uehara M, Hou Q, Kasinath V, Ichimura T, Banouni N, Dai L, Li X, Greiner DL, Shultz LD, Zhang X, Sun ZJ, Curtin I, Vangos NE, Yeoh ZC, Geffken EA, Seo HS, Liu ZX, Heffron GJ, Shah K, Dhe-Paganon S, Abdi R. Direct Tumor Killing and Immunotherapy through Anti-SerpinB9 Therapy. Cell. 2020 Nov 25;183(5):1219-1233.e18. doi: 10.1016/j.cell.2020.10.045. PMID: 33242418
Kiyokawa J, Kawamura Y, Ghouse SM, Acar S, Barçın E, Martínez-Quintanilla J, Martuza RL, Alemany R, Rabkin SD, Shah K, Wakimoto H. Modification of Extracellular Matrix Enhances Oncolytic Adenovirus Immunotherapy in Glioblastoma. Clin Cancer Res. 2020 Nov 30. doi: 10.1158/1078-0432.CCR-20-2400. Online ahead of print. PMID: 33257429
Yang EY, Shah K. Nanobodies: Next Generation of Cancer Diagnostics and Therapeutics. Frontiers in Oncology 2020 Jul 23;10:1182. doi: 10.3389/fonc.2020.01182.. PMID: 32793488
Khalsa JK, Cheng N, Keegan J, Chaudry A, Driver J, Bi WL, Lederer J, Shah, K. Immune phenotyping of diverse syngeneic murine brain tumors identifies immunologically distinct types. Nature Communication 2020 Aug 6;11(1):3912. doi: 10.1038/s41467-020-17704-5. PMID: 32764562
Deng D, Shah K. TRAIL of hope meeting resistance in cancer. Trends in Cancer 2020 Jul 24;S2405-8033(20)30190-4. doi: 10.1016/j.trecan.2020.06.006. PMID: 32718904
Song N, Scholtemeijer M, Shah K. Mesenchymal Stem Cell Immunomodulation: Mechanisms and Therapeutic Potential. Trends in Pharmacological Sciences 2020 Jul 22;S0165-6147(20)30145-0. doi: 10.1016/j.tips.2020.06.009. PMID: 32709406
Levy O, Kuai R, Siren E, Bhere D, Milton Y, Nissar N, De Biasio M, Heinelt M, Reeve B, Abdi R, Alturki M, Fallatah M, Almalik A, Alhasan AH, Shah K*, Karp JM. Shattering barriers toward clinically meaningful MSC therapies. Science Advances 2020 Jul 22;6(30):eaba6884. doi: 10.1126/sciadv.aba6884. * Co-corresponding author. PMID: 32832666
Mineo M, Lyons SM, Zdioruk M, von Spreckelsen N, Ferrer-Luna R, Ito H, Alayo QA, Kharel P, Giantini Larsen A, Fan WY, Auduong S, Grauwet K, Passaro C, Khalsa JK, Shah K, Reardon DA, Ligon KL, Beroukhim R, Nakashima H, Ivanov P, Anderson PJ, Lawler SE, Chiocca EA. Tumor Interferon Signaling Is Regulated by a lncRNA INCR1 Transcribed From the PD-L1 Locus. Molecular Cell. 2020 Jun. 18. doi: 10.1016/j.molcel.2020.05.015. PMID: 32504554
Karakas N, Bay S, Türkel N, Öztunç N, Öncül M, Bilgen H, Shah K, Şahin F, Öztürk, G. Neurons from human mesenchymal stem cells display both spontaneous and stimuli responsive activity. PLoS One. 2020 May 14. doi: 10.1371/journal.pone.0228510. PMID: 32407317
Lee YH, Pang SW, Révai Lechtich E, Shah K, Simon SE, Ponnusamy S, Narayanan R, Poh CL, Tan KO. Tricistronic expression of MOAP-1, Bax and RASSF1A in cancer cells enhances chemo-sensitization that requires BH3L domain of MOAP-1. Journal of Clinical Research and Clinical Oncology. 2020 May 6. doi: 10.1007/s00432-020-03231-9. PMID: 32377840
Bhere D, Arghiani N, Révai Lechtich E, Yao Y, Alsaab S, Bei F, Matin MM, Shah K. Simultaneous downregulation of miR-21 and upregulation of miR-7 has anti-tumor efficacy. Scientific Reports. 2020 Feb. 4. doi: 10.1038/s41598-020-58072-w. PMID: 32019988
Yang Q, Luo C, Zhang X, Liu Y, Wang Z, Cacciamani P, Shi J, Cui Y, Wang C, Sinha B, Peng B, Tong G, Das G, Shah E, Gao Y, Li W, Tu Y, Qian D, Shah K, Akbar M, Zhou S, Song BJ, Wang X. Tartary buckwheat extract alleviates alcohol-induced acute and chronic liver injuries through the inhibition of oxidative stress and mitochondrial cell death pathway. American Journal of Translational Research. 2020 Jan. 15. e-collection PMID: 32051738
Kavari SL, Shah K. Concise Review: Engineered Stem Cells Targeting Multiple Cell Surface Receptors in Tumors. Stem Cells 2020 Jan. doi: 10.1002/stem.3069. PMID: 31381835
2019
Kuruppu D, Bhere D, Farrar CT, Shah K, Brownell AL, Tanabe KK. A model of breast cancer meningeal metastases: characterization with in vivo molecular imaging. Cancer Gene Therapy 2019 May 26. doi: 10.1038/s41417-018-0060-z PMID: 30420717
Martinez-Quintanilla J, Seah I, Chua M, Shah K. Oncolytic viruses: overcoming translational challenges. Journal of Clinical Investigation 2019 Mar. 4. doi: 10.1172/JCI122287. PMID: 30829653
Tanaka S, Luk S, Kiyokawa J, Onozato ML, Iafrate AJ, Shah K, Martuza RL, Rabkin SD, Batchelor TT, Cahill DP, Chi AS, Wakimoto H. Genetically distinct glioma stem-like cell xenografts established from paired glioblastoma samples harvested before and after molecularly targeted therapy. Scientific Reports 2019 Jan. 15. doi: 10.1038/s41598-018-37437-2. PMID: 30644426
Passaro, C, Alayo Q, De Laura I, McNulty J, Grauwet K, Ito H, Bhaskaran V, Mineo M, Lawler SE, Shah K, Speranza MC, Goins W, McLaughlin E, Fernandez S, Reardon DA, Freeman GJ, Chiocca EA, Nakashima H. Arming an oncolytic herpes simplex virus type 1 with a single chain variable antibody against PD-1 for experimental glioblastoma therapy. Clinical Cancer Research 2019 Jan. 1. doi: 10.1158/1078-0432.CCR-18-2311. PMID: 30279232
2018
Reinshagen C, Bhere D, Choi SH, Hutten S, Nesterenko I, Wakimoto H, Le Roux E, Rizvi A, Du W, Minicucci C, Shah K. CRISPR-enhanced engineering of therapy-sensitive cancer cells for self-targeting of primary and metastatic tumors. Science Translational Medicine. 2018 Jul. 11. doi: 10.1126/scitranslmed.aao3240. PMID: 29997250
Bhere D, Khajuria RK, Hendriks WT, Bandyopadhyay A, Bagci-Onder T, Shah K. Therapeutic Neural Stem Cells Engineered During Different Stages of Reprogramming Reveal Varying Therapeutic Efficacies. Stem Cells. 2018 Jun. doi: 10.1002/stem.2805. PMID: 29451340
Heidari P, Kunawudhi A, Martinez-Quintanilla J, Szretter A, Shah K, Mahmood U. Somatostatin receptor type 2 as a radiotheranostic PET reporter gene for oncologic interventions. Theranostics. 2018 May 23. doi: 10.7150/thno.24017. PMID: 29930736
Bhere D, Tamura K, Wakimoto H, Choi SH, Purow B, Debatisse J, Shah K. microRNA-7 upregulates death receptor 5 and primes resistant brain tumors to caspase-mediated apoptosis. Neuro Oncolology. 2018 Jan 22. doi: 10.1093/neuonc/nox138. PMID: 29016934